Psyence receives MHRA approval for Phase 2 trial
Psyence Group (“Psyence”) has announced formal approval from the UK’s Medicines and Healthcare Regulatory Agency (MHRA) to commence their highly anticipated Phase 2 trial.
Psyence Group Receives Phase IIa Clinical Trial Approval from the UK Medicines and Healthcare Products Regulatory Agency (MHRA)
Psyence has partnered with a leading psychedelic Contract Research Organisation (CRO), Clerkenwell Health, to design and deliver the clinical trial. Clerkenwell has experience in conducting psychedelic research and the trial will be conducted at two centers in the United Kingdom.
Hannam & Partners Independent Research Report
Hannam & Partners issued an independent research report on Psyence identifying it as a first mover into the palliative care market supported by natural psilocybin production.
Psyence Group Announces Amendment and Closing of Previously Announced Private Placement
We are pleased to announce, further to the Company’s press release dated December 2, 2021, the amendment and closing of its first tranche of the previously announced non-brokered private placement offering (the “Private Placement”) raising gross process of $1.273 million.
Psyence Taps Another Pharma Exec To Drive Its Clinical Program
Psyence Taps Another Pharma Exec To Drive Its Clinical [...]
Psyence and Filament Health Enter Into Exclusive Licensing Agreements For Natural Psilocybin Products
Psyence and Filament Health Enter Into Exclusive Licensing Agreements [...]
Psyence to Present at the H.C Wainwright 2nd Annual Psychedelics Conference December 6
Psyence to Present at the H.C Wainwright 2nd Annual Psychedelics Conference December 6
Psyence Group Announces Private Placement
Psyence announces that it is commencing a non-brokered private placement offering of up to CAD$2,000,000 of unsecured convertible promissory notes (the “Notes”).
Psyence Group Functional Mushroom Brand “GOODMIND™” Commences National Roll-Out In South Africa’s Largest Coffee Retail Chain
Psyence is pleased to announce that its joint venture functional mushroom brand GOODMINDTM has partnered with one of Africa’s largest coffee retail chains, “vida e caffè”, to commence the rollout of its GOODMINDTM functional mushroom brand in select vida e caffè’s coffee shops in South Africa.
Psyence Group Invited as First Psychedelic Company to present at the 15th-Annual Global Wellness Summit
Psyence’s Head of Corporate Social Responsibility, Mary-Elizabeth Gifford, will host an in-person keynote conversation with Rick Doblin, PhD, Founder and Executive Director of the Multidisciplinary Association for Psychedelic Studies (MAPS) on the future of Psychedelics and Healing.